Back to the articles
New Study Reveals Promising Results for Helicobacter pylori Eradication with Lacidofil®
A new study highlights the potential of Lacidofil® as an adjuvant to standard therapy as an effective approach for Helicobacter pylori eradication.
“Backed by over 29 positive clinical trials with over 1,000 participants and pre-clinical scientific evidence, Lacidofil® has consistently demonstrated its beneficial effects on maintaining a healthy intestinal microbiota, leading to overall well-being. This new study strengthens the evidence already available showing that Lacidofil® is an effective adjuvant to standard therapy for H. pylori eradication and reduces the side effects of the antibiotics in this therapy” confirms Marie-Laure Oula, Clinical Program Manager at Lallemand Health Solutions.
This new double-blind, randomized, placebo-controlled study [Kiattiweerasak, 2023] shows the efficacy and safety of Lacidofil® a unique formula combining two proprietary probiotic bacteria strains L. rhamnosus Rosell®-11 and L. helveticus Rosell®-52. The study included 90 adults, taking either a placebo or Lacidofil® with standard triple therapy for two weeks and then continued with either the placebo or the probiotic alone for four additional weeks. Gastrointestinal comfort and general health-related quality of life criteria were analyzed at baseline, and after two and six weeks of probiotic intervention. The analyses showed a statistically significant decrease of gastrointestinal discomfort and increase of general health-related quality of life at week six compared to placebo group (p<0.001 and p=0.02, respectively). The study also highlights that Lacidofil® is able to increase the eradication rate of H. pylori (p=0.047).
Lacidofil® has been on the market since 1995 and is now available in over 20 countries, both as a standalone product and as an ingredient in combination with other strains. With a proven record of safe use and a robust pharmacovigilance program, Lacidofil® has earned strong Canadian claims approval for various health applications, including promoting healthy microflora in infants as young as 2 months old, addressing Antibiotic-Associated Diarrhea (AAD), managing acute diarrhea, supporting GI balance during Helicobacter pylori eradication therapy, and offering specific benefits for pregnant women.
Offered in various galenic forms, including powders, capsules, and drops, Lacidofil® is a versatile probiotic solution meeting market demand.
For more information about Lacidofil® and its range of health applications, please contact us at firstname.lastname@example.org
The findings of this study were published in Frontiers in Gastroenterology
About Lallemand Health Solutions – Leading Probiotics Forward
Lallemand Health Solutions is a pioneering company recognized as a vertically integrated global leader in manufacturing probiotic yeast and bacteria-based formulas. These formulas are designed for human health supplements, food applications, and nutricosmetics. Lallemand Health Solutions’ probiotics are documented to deliver benefits in gut health, immune support, mental well-being, women’s health, skin care, oral health, and metabolic health. With manufacturing processes adhering to the highest quality standards, including Good Manufacturing Practices, and an ambitious research and development program, Lallemand Health Solutions provides partners with probiotic strains and formulas that are marketed in over 60 countries across five continents.
Marilou Luneau, Communications Manager
Lallemand Health Solutions